Johnson & Johnson was cautiously lauded for its clinical trial data-sharing initiative, but Roche's project was pilloried. Now Novartis has joined its Swiss peer in rolling out an underwhelming transparency program.
As the biosimilar market takes shape, companies are gunning to produce copies of some of the world's top-selling drugs. And according to a new Moody's report, with their star products wearing targets on their backs, AbbVie, Amgen and Roche are most exposed to the new competition.
The BMJ and others spent years trying to get Roche to release Tamiflu data, and the criticism continued even after the Swiss pharma put in a new results-sharing policy. Now, Roche is facing a situation where sharing trial data may be the best way to clear up the effect of Avastin on brain cancer.
Should Avastin really join the small set of tools in the brain-cancer toolbox? With studies offering conflicting results, Roche and some outside researchers may share data to answer that question.
Roche's new extended partnership with Cancer Genetics will expand molecular diagnostic cancer testing in the Caribbean and Central America as part of a three-year deal.
Last year, Roche appeared to throw in the towel on its breast cancer drug Herceptin in India when it said it would not defend the patent there. But it has come back out swinging with a court action that has messed with this week's launch of a biosimilar from Mylan.
In the biotech and pharma industries, drug delivery is a crucial aspect of research and development. Finding new ways to deliver old drugs, ways to make a new drug more efficient or ways that make a...
The National Institute for Health and Care Excellence, Britain's drug-review agency, is no longer recommending that Roche's targeted lung cancer drug Tarceva be used as a second-line treatment in patients with non-small cell lung cancer who have relapsed—sparking an angry response from the Swiss drugmaker.
Swiss pharma giant Roche has had a few glitches of late, with the loss of its R&D chief to Google and the recent failure of its highly anticipated experimental schizophrenia drug. But it was positive news today as the company reported 2013 growth fueled by strong sales of its cancer drugs.
By last summer, Roche's R&D complex in Nutley, N.J. resembled a movie set for the latest post-Apocalypse tale, its largely empty buildings home to a few hardy survivors as new digs were being prepared in Manhattan.